Clinical trial

Hypersensitivity Pneumonitis of Domestic Origin: Investigation of the Microorganisms Involved and Improvement of Serological Diagnosis.

Name
2022/736
Description
Exposure to molds in dwellings is a public health problem. Diagnosis of hypersensitivity pneumonitis due to mold exposure at home (domestic HP) are increasing. To perform the serodiagnosis of domestic HP a cohort constitued of proven cases and exposed healthy controls are needed. The HOME HP study aimed at obtaining a cohort of proven cases and exposed controls in order to be able to improve the serodiagnosis of domestic HP.
Trial arms
Trial start
2023-02-01
Estimated PCD
2026-03-01
Trial end
2026-03-01
Status
Not yet recruiting
Treatment
blood sample
the patient will have a blood sample in order to perform serology tests
Arms:
domestic HP
Size
500
Primary endpoint
measurement of mold sensitisation
2 years
measurement of mold presence in dwellings
2 years
testing of new fungal antigens
2 years
Eligibility criteria
Inclusion Criteria: * exposure to mold at home * given consent * suspicion of doemstic HP * clinical signs of interstial pneumopathy Exclusion Criteria: * immunocompromised patients * prior diagnosis of another HP form (avian, farm, bath tub etc..) * exposure to avian proteins
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'interventionModelDescription': 'the final diagnosis will be judged by the pneumologist on plural results: imagery, BALF cytology. The final diagnosis will be used to make 2 groups proven / non proven domestic forms', 'primaryPurpose': 'DIAGNOSTIC', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 500, 'type': 'ESTIMATED'}}
Updated at
2023-01-30

1 organization

1 product

3 indications

Indication
Sensitization